AstraZeneca Gets Puma Tossed From Tagrisso Patent Royalties Suit

Puma Biotechnology Inc. was tossed from a lawsuit seeking royalties from AstraZeneca Plc’s blockbuster Tagrisso, but a federal judge mostly denied AstraZeneca’s bids for early wins against patent-infringement claims from Pfizer Inc’s Wyeth unit.

Puma’s exclusive license to Wyeth LLC’s US Patent Nos. 10,603,314 and 10,596,162 doesn’t include Tagrisso’s active ingredient, osimertinib, so the alleged infringing activity falls outside the scope of its license, Judge Matthew F. Kennelly wrote in an opinion issued Monday in the US District Court for the District of Delaware. Kennelly dismissed Puma for lack of standing but denied AstraZeneca’s motion with respect to Wyeth.

“Although ...